Alivus Life Sciences Limited (BOM:543322)
India · Delayed Price · Currency is INR 1,056.55
-13.85 (-1.29%)
At close: May 29, 2026
Alivus Life Sciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 5,645 | 4,856 | 4,709 | 4,670 | 4,187 |
Depreciation & Amortization | 753.57 | 583.42 | 497.78 | 406.48 | 369.2 |
Other Amortization | - | 22.67 | 36.74 | 14.46 | 9.57 |
Loss (Gain) From Sale of Assets | 5.4 | 23.02 | 10.11 | 5.58 | 7.43 |
Loss (Gain) From Sale of Investments | -380.56 | -76.15 | 31.66 | - | - |
Stock-Based Compensation | - | - | 43.75 | 31.85 | 34.98 |
Provision & Write-off of Bad Debts | - | - | - | 3.71 | 48.19 |
Other Operating Activities | 916.3 | 309.79 | 147.03 | 64.97 | 320.84 |
Change in Accounts Receivable | -887.54 | -2,048 | 378.6 | -1,336 | -592.15 |
Change in Inventory | -674.47 | -388.55 | -826.26 | -972.27 | -28.23 |
Change in Accounts Payable | -126.77 | 187.46 | -341.21 | 907.79 | 737.49 |
Change in Other Net Operating Assets | 403.37 | 445.2 | -551.93 | -735.63 | 881.29 |
Operating Cash Flow | 5,654 | 3,915 | 4,135 | 3,060 | 5,976 |
Operating Cash Flow Growth | 44.41% | -5.32% | 35.13% | -48.79% | 53.97% |
Capital Expenditures | -3,071 | -1,662 | -1,290 | -1,628 | -1,322 |
Sale of Property, Plant & Equipment | 6.47 | 6.29 | 4.65 | 1.74 | 4.69 |
Investment in Securities | -2,647 | -4,701 | - | 1.11 | 28.05 |
Other Investing Activities | 9.66 | 200.13 | 120.21 | 157.66 | 66.7 |
Investing Cash Flow | -5,702 | -6,156 | -1,165 | -1,467 | -1,222 |
Short-Term Debt Repaid | - | - | - | - | -9,329 |
Long-Term Debt Repaid | -80.21 | -44.86 | -22.09 | -11.28 | -13.65 |
Total Debt Repaid | -80.21 | -44.86 | -22.09 | -11.28 | -9,342 |
Net Debt Issued (Repaid) | -80.21 | -44.86 | -22.09 | -11.28 | -9,342 |
Issuance of Common Stock | 103.94 | 6.69 | - | - | 10,119 |
Common Dividends Paid | -613.41 | - | -2,757 | -3,859 | -1,287 |
Other Financing Activities | -53.72 | -24.14 | -15.46 | -5.47 | -277.64 |
Financing Cash Flow | -643.4 | -62.31 | -2,794 | -3,876 | -787.96 |
Net Cash Flow | -690.8 | -2,304 | 175.91 | -2,283 | 3,966 |
Free Cash Flow | 2,584 | 2,253 | 2,845 | 1,432 | 4,654 |
Free Cash Flow Growth | 14.65% | -20.81% | 98.69% | -69.23% | 45.39% |
Free Cash Flow Margin | 10.12% | 9.44% | 12.46% | 6.63% | 21.92% |
Free Cash Flow Per Share | 21.01 | 18.34 | 23.19 | 11.69 | 39.60 |
Cash Interest Paid | 53.72 | 24.14 | 15.46 | 5.47 | 277.64 |
Cash Income Tax Paid | 1,733 | 1,630 | 1,630 | 1,536 | 1,382 |
Levered Free Cash Flow | 1,713 | 1,390 | 2,108 | 553.75 | 3,756 |
Unlevered Free Cash Flow | 1,747 | 1,405 | 2,117 | 557.17 | 3,931 |
Change in Working Capital | -1,285 | -1,804 | -1,341 | -2,137 | 998.4 |